Beckman Abandons High-Content Screening Technology, Staffers as Part of Restructuring | GenomeWeb

Beckman Coulter's San Diego-based Cell Analysis and Development Center — which houses R&D and service for the IC 100 high-content screening technology that Beckman acquired along with startup Q3DM in late 2003 — is one of the at least three facilities that Beckman said it plans to close as part of its recently announced reorganization, according to sources close to the situation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.